Irbesartan E Idroclorotiazide Mylan

Irbesartan, the active ingredient in Irbesartan E Idroclorotiazide Mylan, is an angiotensin II receptor blocker (ARB) presented as a tablet for oral use. It treats hypertension in adult patients, often in combination with a thiazide diuretic to improve blood pressure control, and is indicated for patients whose blood pressure remains uncontrolled with monotherapy, offering a convenient fixed‑dose regimen.

GNH USA supplies Irbesartan E Idroclorotiazide Mylan as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, adhering to EU GMP standards and providing reliable global distribution.

Irbesartan/Hydrochlorothiazide is indicated for the management of hypertension, a condition characterized by elevated arterial pressure.

- Essential hypertension: lowers systolic and diastolic blood pressure, reducing cardiovascular risk. - Hypertension requiring diuretic therapy: adds thiazide diuretic effect to improve fluid balance and enhance antihypertensive efficacy. - Hypertension uncontrolled by monotherapy: provides a fixed‑dose combination that simplifies treatment and may improve adherence.

The combination of irbesartan and hydrochlorothiazide may cause a range of adverse reactions, which are categorized by frequency.

Common Side Effects: - Dizziness or light‑headedness - Headache - Fatigue - Increased urination - Electrolyte disturbances (e.g., low potassium) - Mild gastrointestinal upset

Serious or Rare Side Effects: - Severe allergic reaction (anaphylaxis) - Significant drop in blood pressure (hypotension) - Acute kidney injury - Hyperkalemia - Pancreatitis - Blood disorders such as agranulocytosis

When prescribing Irbesartan/Hydrochlorothiazide, clinicians should observe several precautionary measures to ensure patient safety.

- Monitor blood pressure: adjust therapy if target levels are not achieved. - Check electrolytes: especially potassium and sodium levels during treatment. - Assess renal function: periodic serum creatinine and eGFR testing is recommended. - Use caution in hepatic impairment: dose adjustments may be required. - Avoid use in pregnancy: drug may harm the fetus; contraindicated. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Irbesartan/Hydrochlorothiazide can interact with other medicines, affecting efficacy or safety.

Major Interactions (Avoid): - Aliskiren (especially in diabetes): may increase risk of renal impairment and hyperkalemia. - Potassium‑sparing diuretics or supplements: risk of dangerous hyperkalemia. - Lithium: concurrent use can raise lithium levels, leading to toxicity. - ACE inhibitors or other ARBs: combined use may cause excessive potassium rise and renal dysfunction. - NSAIDs (e.g., ibuprofen): may reduce antihypertensive effect and impair kidney function.

Moderate Interactions (Monitor Closely): - Other antihypertensive agents (beta‑blockers, calcium channel blockers): may cause additive blood pressure lowering. - CYP3A4 inhibitors (ketoconazole, itraconazole): can increase irbesartan plasma concentrations. - Antacids containing aluminum or magnesium: may decrease absorption of irbesartan. - Thiazide diuretics with other diuretics: monitor electrolyte balance. - Warfarin: may enhance anticoagulant effect; monitor INR.